Evidence map›Paper›PMID 35342138›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan.

Takayuki Fujii, Masao Hagihara, Keiko Mitamura, Shiori Nakashima, Shin Ohara, Tomoyuki Uchida, Morihiro Inoue, Moe Okuda, Atsuhiro Yasuhara, Jurika Murakami and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Takayuki FujiiDepartment of Hematology, Eiju General Hospital, Japan.
Masao HagiharaDepartment of Hematology, Eiju General Hospital, Japan.
Keiko MitamuraDivision of Infection Control, Eiju General Hospital, Japan.
Shiori NakashimaDepartment of Hematology, Eiju General Hospital, Japan.
Shin OharaDepartment of Hematology, Eiju General Hospital, Japan.
Tomoyuki UchidaDepartment of Hematology, Eiju General Hospital, Japan.
Morihiro InoueDepartment of Hematology, Eiju General Hospital, Japan.
Moe OkudaDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Atsuhiro YasuharaDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Jurika MurakamiDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Calvin DuongDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Kiyoko Iwatsuki-HorimotoDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Seiya YamayoshiDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Yoshihiro KawaokaDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Eiju General Hospital · JPNational Center for Global Health and Medicine · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Although the relationship between anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies and COVID-19 severity has been reported, information is lacking regarding the seropositivity of patients with particular types of diseases, including hematological diseases. Methods In this single-center, retrospective study, we compared SARS-CoV-2 IgG positivity between patients with hematological diseases and those with non-hematological diseases. Results In total, 77 adult COVID-19 patients were enrolled. Of these, 30 had hematological disorders, and 47 had non-hematological disorders. The IgG antibody against the receptor-binding domain of the spike protein was detected less frequently in patients with hematological diseases (60.0%) than in those with non-hematological diseases (91.5%; p=0.029). Rituximab use was significantly associated with seronegativity (p=0.010). Conclusion Patients with hematological diseases are less likely to develop anti-SARS-CoV-2 antibodies than those with non-hematological diseases, which may explain the poor outcomes of COVID-19 patients in this high-risk group.

Indexed as

COVID-19Hematologic DiseasesAdultAntibodies, ViralHumansImmunoglobulin GImmunoglobulin MJapanRetrospective StudiesSARS-CoV-2Antibodies, ViralImmunoglobulin GImmunoglobulin MCOVID-19SARS-CoV-2SARS-CoV-2 IgG antibodies

Identifiers

PMID35342138
PMCPMC9259303
OpenAlexW4221101837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.